Weight loss is the intervention with the clearest graded effect on fatty liver: the more weight comes off, the more the liver changes. That much is well evidenced. The part usually left out of the headline is the denominator — in the study that produced the famous figures, most participants never reached the amount of weight loss that produced them. Both halves are the article.

MASLD and MASH: MASLD is fat accumulating in the liver in someone who does not drink heavily — the condition was previously called non-alcoholic fatty liver disease. MASH is the inflamed form, in which the liver is not just fatty but irritated, and it is the form that can go on to scar.

How much weight loss does it take?

More than most people manage, and the study everyone quotes is also the best evidence for that.

Vilar-Gomez followed 293 patients with biopsy-confirmed steatohepatitis for 52 weeks in a single-arm study of lifestyle modification, taking a second biopsy at the end. The amount of weight lost was independently associated with improvement in every histological measure they tracked, and among the participants who lost at least 5% of body weight, 58% had resolution of steatohepatitis — significantly more than among those who lost less (Vilar-Gomez 2015).

Now the denominator that travels with those figures. Only 88 of the 293 participants — 30% — reached 5% weight loss at all. Across the whole group, 25% achieved resolution of steatohepatitis and 19% had regression of fibrosis (Vilar-Gomez 2015).

Seven in ten did not even reach the 5% mark, and the study's best results sat higher still.

Why that denominator is the whole story

Because the encouraging percentages describe the minority who got there, and the discouraging ones describe everybody.

Both are true at once and they point in opposite directions. The dose-response is real: this is one of the few places in weight-loss medicine where you can watch tissue change in proportion to weight lost, measured on biopsy rather than inferred from a blood test. And the dose is the hard part. The study demonstrates simultaneously that enough weight loss changes the liver, and that a year of supervised lifestyle modification did not get most people to enough.

The study reports still better results in the participants who lost 10% or more. It does not report how many of them there were, so this page does not quote those figures — a percentage without its denominator is the thing this section is warning about.

Both halves point at the same practical conclusion: what matters is the size of the weight loss and whether it holds, rather than the fact of having started. A programme that produces 3% and stops has produced the cohort average, not the headline.

What Singapore actually knows about it

Very little, and saying so is more useful than filling the gap.

There is no national guideline on fatty liver. Singapore's complete published set of 29 ACE Clinical Guidances covers hypertension, lipids, chronic kidney disease, gestational diabetes and much else, and contains nothing on fatty liver — a reader can check that list directly (ACE repository). There is no national screening programme for it either. Its only appearance in national guidance is inside the Healthier SG list of conditions that, alongside a BMI of 32.5 or above, can qualify a patient for bariatric referral (MOH protocol).

Which means the prevalence percentages circulating for Singapore should be traced to their source before they are believed. The ones in circulation come from small convenience samples rather than from a population survey, and this page is not going to add another number to that pile.

What the national data does say is about body weight rather than the liver. Across 2023 to 2024, obesity among adults aged 18 to 74 was 12.7% — up significantly from 10.5% in 2019 to 2020 — and it varied sharply by ethnicity, at 31.7% among Malays, 19.3% among Indians and 8.4% among Chinese. Separately, 22.8% of adults sat at or above the Asian high-risk BMI threshold of 27.5, a figure the survey reports by sex rather than by ethnicity (NPHS 2024).

What the national protocol says about weight

Singapore's primary-care protocol sets a weight-loss target of 5 to 10% of body weight over 6 to 12 months, and sets medication indications at a BMI of 30 and above, or 27.5 to 29.9 among Asians with co-morbidities or complications of obesity (MOH protocol).

Read that beside the previous section and the two line up: the national target band and the band where liver histology visibly changes are approximately the same 5 to 10%. That is a coincidence of numbers rather than a liver-specific recommendation — the protocol is about body weight, not about the liver — but it means the target a Singapore GP would set is in the right region.

Where the drug evidence sits, and why it is not this article

No medicine in this class is registered in Singapore for fatty liver (Singapore NDF), so what follows is trial evidence rather than a description of an available treatment.

The largest trial to report is a planned 72-week interim analysis of a study designed to run 240 weeks. Its most quoted number needs its comparator attached: 34.3% of the placebo group also met the steatohepatitis resolution endpoint (Sanyal 2025). An interim analysis with a placebo response that size is a reason to wait for the full result rather than to conclude from it. What the outcome trials in this drug class measured, and in whom, is set out in the long-term effects of GLP-1 medication.

Where this sits beside our criteria

Our eligibility criteria are a BMI of 25 and above alongside a related health condition. Fatty liver is one of the conditions that can qualify. Being eligible on account of a condition and being treated for that condition are different things: GetLean is a weight-management service, and a liver condition is managed by the doctor already looking after it.

We do not order, interpret or follow up liver investigations. If you want to know whether your own liver has changed, that is answered by the doctor monitoring it and by a repeat investigation — not by a weight figure, and not by this page.

How the BMI thresholds work, and which conditions count, is in am I eligible. The closest neighbour to this article is prediabetes and body weight, since the two conditions travel together, and blood pressure and body weight covers the third. The cluster sits under conditions and body weight.

Common questions

How much weight do I need to lose for fatty liver?

In the largest biopsy-based study, 58% of the participants who lost at least 5% of body weight had resolution of steatohepatitis. The same study is a warning about how hard that is: only 30% of the 293 participants reached 5% at all (Vilar-Gomez 2015).

Can fatty liver be reversed?

Liver fat can fall and inflammation can settle with sustained weight loss, and the effect is proportional to how much weight comes off (Vilar-Gomez 2015). Whether that has happened in any individual is a question for the doctor monitoring the liver, answered on a repeat investigation rather than on the scale.

How common is fatty liver in Singapore?

There is no figure worth quoting. Singapore has no national guideline on fatty liver and no screening programme (ACE repository), and the percentages in circulation come from small convenience samples rather than a population survey.

Is there a Singapore guideline for fatty liver?

No. The complete published set of 29 ACE Clinical Guidances contains none (ACE repository). Fatty liver's only appearance in national guidance is within the Healthier SG list of conditions that can qualify a patient for bariatric referral (MOH protocol).

Does fatty liver mean I drink too much?

No. This form is defined by fat accumulating in the liver in the absence of heavy alcohol intake, which is why its name refers to metabolic dysfunction rather than to alcohol.